Download This Paper
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Temporal Trends in the Epidemiology of Inflammatory Bowel Diseases in the Public Healthcare System in Brazil: A Large Population-Based Study
38 Pages Posted: 22 Feb 2022
More...Abstract
Background: Population-based data on epidemiology of Inflammatory Bowel Diseases (IBD) in Brazil is scarce. This study aims to define temporal trends of incidence and prevalence rates of Crohn’s disease (CD) and ulcerative colitis (UC) in Brazil.
Methods: All IBD patients from the public healthcare national system were included from January 2012 to December 2020. Average Annual Percent Change (AAPC) and 95% confidence intervals (CI) were calculated using log-linear regression for incidence and binomial regression for prevalence. Moran’s I autocorrelation index was used to analyze clustering of cities by level of prevalence.
Results: A total of 212,026 IBD patients. Incidence of IBD rose from 9.41 in 2012 to 9.57 per 100,000 in 2020 (AAPC=0.80%; 95% CI -0.37, 1.99); for UC, incidence increased from 5.69 to 6.89 per 100,000 (AAPC=3.04; 95% CI 1.51, 4.58) and for CD incidence decreased from 3.71 to 2.68 per 100,000 (AAPC=-3.24%; 95% CI -4.45, -2.02). Prevalence of IBD increased from 30.01 in 2012 to 100.13 per 100,000 in 2020 (AAPC=14.87%; CI 14.78-14.95); for UC, from 15.77 to 56.53 per 100,000 (AAPC=16.06%; CI 15.94, 16.17); for CD from 12.61 33.68 per 100,000 (AAPC=12.09% CI 11.95, 12.02). A south-north gradient was observed in 2020 prevalence rates of IBD [i=0.404052 (p<0.001)], CD [i=0.218942 (p<0.001)] and UC [i=0.416051 (p<0.001)].
Conclusions: Incidence of CD is decreasing whereas of UC is increasing, leading to stabilization in the incidence of IBD from 2012 to 2020 in Brazil. Prevalence of IBD has been climbing with 0.1% of Brazilians living with IBD in 2020.
Funding Information: None
Declaration of Interests: Quaresma AB has received honoraria for speaking from AbbVie, Apsen and Janssen.
Aderson OMCD has received honoraria for speaking from AbbVie, Janssen, Pfizer, and Takeda; he has been a consultant for Takeda, AbbVie, and Janssen.
Coy CSR has no conflicts of interest.
Magro DO has no conflicts of interest.
Hino AAF has no conflicts of interest.
Valverde DA is CEO of Techtrials a Healthcare Data Science Company.
Panaccione R reports consulting from AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance Biopharma, UCB, and Takeda Pharmaceuticals. He has received speaker’s fees from AbbVie, Arena Pharmaceuticals, Celgene, Eli Lilly, Ferring, Gilead Sciences, Janssen, Merck, Pfizer, Roche, Sandoz, Shire, and Takeda Pharmaceuticals.
Coward SB has no conflicts of interest.
Ng SC has received consulting and speaker fees from AbbVie, Ferring, Janssen, Menarini, and Takeda; served as a Scientific Advisory Board member for AbbVie, Ferring, and Takeda; and received research grants from AbbVie, Ferring, and Janssen.
Kaplan GG has received honoraria for speaking or consultancy from AbbVie, Janssen, Pfizer, Amgen, and Takeda. He has received research support from Ferring, Janssen, AbbVie, GlaxoSmith Kline, Merck, and Shire. He has been a consultant for Gilead. He shares ownership of a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE, AND PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. 7 Sept. 2018.
Kotze PG has received consulting and speaker fees from AbbVie, Janssen, Pfizer, Takeda and Takeda. He also received scientific grants from Pfizer and Takeda
Ethics Approval Statement: This study was approved by the Research Ethics Committee of the University of the West of Santa Catarina (UNOESC), in accordance with the Certificate of Presentation for Ethical Appreciation (CAAE) 97905918.7.0000.5367. During all stages of this research, all guidelines of Resolution 466/2012 of the National Health Council were strictly followed and complied.
Keywords: Incidence, prevalence, inflammatory bowel disease, ulcerative colitis, crohn's disease, epidemiology, Brazil
Suggested Citation: Suggested Citation